Results from the US PATRIOT-II trial showed a significant improvement in PFS and OS with avelumab plus best supportive care (BSC) vs BSC alone in patients with locally advanced or metastatic urothelial cancer who had not progressed on frontline platinum-based chemotherapy. Most patients were White (89.4%), non-Hispanic or Latino (78.1%), and had an ECOG performance status of 0 (42.5%) or 1 (33.1%)